Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Terminated Phase 3 Interventional Results available

A Phase 3 Efficacy Study Of Dimebon In Patients With Moderate To Severe Alzheimer's Disease

ClinicalTrials.gov ID: NCT00912288

Public ClinicalTrials.gov record NCT00912288. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 3, 2026, 8:48 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled 26-Week Trial To Evaluate The Efficacy And Safety Of Dimebon In Patients With Moderate-To-Severe Alzheimer's Disease

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

No Dimebon clinical data exist yet in patients with disease that has advanced to the moderate-to-severe stage. Therefore, this study evaluates the safety and efficacy of Dimebon in patients with moderate-to-severe AD who are receiving existing background therapy with memantine.

Study identification

NCT ID
NCT00912288
Recruitment status
Terminated
Study type
Interventional
Phase
Phase 3
Lead sponsor
Pfizer
Industry
Enrollment
86 participants

Conditions and interventions

Interventions

Drug

Eligibility (public fields only)

Age range
50 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Aug 31, 2009
Primary completion
Jul 31, 2010
Completion
Jul 31, 2010
Last update posted
Oct 1, 2012

2009 – 2010

United States locations

U.S. sites
21
U.S. states
14
U.S. cities
20
Facility City State ZIP Site status
Pfizer Investigational Site Phoenix Arizona 85006
Pfizer Investigational Site Costa Mesa California 92626
Pfizer Investigational Site Encino California 91316
Pfizer Investigational Site Los Alamitos California 90720
Pfizer Investigational Site Newport Beach California 92660-2452
Pfizer Investigational Site Newport Beach California 92663
Pfizer Investigational Site Denver Colorado 80218
Pfizer Investigational Site New Haven Connecticut 06510
Pfizer Investigational Site Brooksville Florida 34601
Pfizer Investigational Site Delray Beach Florida 33445
Pfizer Investigational Site West Palm Beach Florida 33407
Pfizer Investigational Site Indianapolis Indiana 46260
Pfizer Investigational Site Lexington Kentucky 40503
Pfizer Investigational Site Pittsfield Massachusetts 01201
Pfizer Investigational Site Princeton New Jersey 08540
Pfizer Investigational Site Rochester New York 14620
Pfizer Investigational Site Syracuse New York 13210
Pfizer Investigational Site Norristown Pennsylvania 19401
Pfizer Investigational Site East Providence Rhode Island 02914
Pfizer Investigational Site Cordova Tennessee 38018
Pfizer Investigational Site Middleton Wisconsin 53562

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 26 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00912288, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Oct 1, 2012 · Synced Sep 3, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00912288 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →